Welcome to our dedicated page for CG Oncology news (Ticker: CGON), a resource for investors and traders seeking the latest updates and insights on CG Oncology stock.
CG Oncology, Inc. (NASDAQ: CGON) is a late-stage clinical biopharmaceutical company whose news flow centers on the development of cretostimogene grenadenorepvec, an intravesically delivered oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). Company updates frequently highlight progress in its Phase 3 and Phase 2 clinical programs across high-risk BCG-unresponsive, high-risk BCG-naïve, BCG-exposed, and intermediate-risk NMIBC populations.
Investors and healthcare professionals following CGON news can expect regular announcements on clinical trial milestones, such as completion of enrollment in the PIVOT-006 Phase 3 study in intermediate-risk NMIBC, updated efficacy and safety data from the BOND-003 registrational trial in high-risk BCG-unresponsive disease, and emerging results from the CORE-008 Phase 2 trial. The company also issues releases on regulatory developments, including initiation of a rolling Biologics License Application submission to the U.S. FDA for cretostimogene in high-risk BCG-unresponsive NMIBC with carcinoma in situ with or without Ta/T1 disease.
CG Oncology’s news stream additionally covers scientific presentations and collaborations, such as late-breaking abstracts and posters at the Society of Urologic Oncology Annual Meeting, participation in major healthcare investor conferences, and support of the CG-SUO-CTC NMIBC Research Fellowship aimed at advancing clinical research in bladder cancer. Corporate governance and leadership changes, including board appointments and transitions in financial leadership, are disclosed through both press releases and Form 8-K filings.
This CGON news page aggregates these updates so readers can track key developments in cretostimogene’s clinical performance, regulatory interactions, research partnerships, and corporate events over time.
CG Oncology, Inc. announced positive Phase 3 BOND-003 study results for cretostimogene monotherapy in treating high-risk, BCG-unresponsive Non-Muscle Invasive Bladder Cancer. The study showed a 75.2% complete response rate with durable responses over 12 months. No Grade 3 or higher treatment-related adverse events were reported. Cretostimogene has the potential to be a preferred therapy over surgical options in this patient population.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.